- Clearmind Medicine engages the Independent Trading Group as a market maker and Thunder11 as a PR agency
- ITG will trade shares of Clearmind on the CSE and all other trading venues
- Thunder11 will be involved in raising Clearmind’s profile in the U.S. with analysts, media, partners and other influential audiences
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics - Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines
- Clearmind Medicine Inc. (CMND) is up 3.57 per cent, trading at C$0.58 at 9:49 am EST
Clearmind Medicine Inc. (CMND) has engaged the services of Independent Trading Group to provide market-making services.
ITG will trade shares of Clearmind on the CSE and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of its common shares.
It also retained Thunder11 as a PR Agency. Thunder11 will be involved in raising Clearmind’s profile in the U.S. with analysts, media, partners and other influential audiences.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Its intellectual portfolio currently consists of four patent families.
Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind Medicine Inc. (CMND) is up 3.57 per cent, trading at C$0.58 at 9:49 am EST.
